ENO1 and COVID-19: These additional protein targets, which have been documented in both pre-COVID autoimmune cardiomyopathies and in COVID-19 autoimmune cardiopathies, included angiotensin converting enzyme 2 (ACE2) [51,98,99,100], antineutrophil cytoplasmic antibodies (ANCA) [101,102,103], alpha enolase [104], alpha- and beta-adrenergic receptors [42,105,106,107,108,109], laminins [110], phospholipids [111,112,113], tropomyosin [114], and troponin [104,115,116].